


EXPANDING ACCESS TO HEALTH


We collaborate with key stakeholders globally to advance access to health, make our products accessible and affordable and address systemic barriers to care where we can have the greatest impact.



Progress doesn't just happen. It's built—by people, with purpose.
Progress means little if it doesn't reach those who need our medicines and vaccines.

450M+ PEOPLE

reached with our medicines and vaccines in 2024.¹



Journey Through Our Guiding Principles

Discovery & Invention

Invent medicines and vaccines to **address vital global health needs where we can have the greatest impact.**



Availability

Make available a reliable, safe global supply of quality medicines and vaccines, and invest in solutions to deliver timely access to our products in a responsible and sustainable manner.



Affordability & Sustainable Access



Develop and implement sustainable access solutions that address barriers to affordability and **enable more people to access our products.**

We collaborate with



and other partners to create sustainable access to our innovative medicines and vaccines.

Strengthening Health Systems & Addressing Barriers to Health Care

We are committed to strengthening health systems and reducing barriers to quality care.

In 2024

We provided **\$43 million** in social investments to address health equity through²



11.4 MILLION

people reached by our social investments in low- and middle-income countries and underserved populations in high-income countries.³

Learn more in our *Purpose for Progress: 2024/2025 MSD Impact Report* at <https://www.msd.com/company-overview/sustainability/>

¹ This people reached metric estimates the number of people who have received a company product through commercial channels, clinical trials, voluntary licensing or product donations. Product donations include people reached through the MECTIZAN Donation Program, U.S. Patient Assistance Programs, and the MSD Medical Outreach Program. Sources of data are Merck & Co., Inc., Rahway, NJ, USA and third-party data sets that are tracked within an enterprise-wide internal database. The people reached metric for all sources is calculated as doses sold divided by the average dose schedule for a given market in a given year. People taking multiple products may be counted as multiple people toward the total estimate. In some instances, this estimate may include people enabled to access our products through access solutions, which are calculated as part of our goal to enable access to our innovative medicines and vaccines (page 31). The people reached metric does not include people reached through social investments, which are calculated as part of our goal to further advance access to health for populations in LMICs and groups with limited access to care in high-income countries (page 38). Represents investments made by our Office of Social Business Innovation.

² (a) Social investments include our Company's philanthropic partnerships, programs and impact investments. "Underserved populations" are defined as those that face health disparities due to disadvantages related to insurance status, social determinants of health, race, ethnicity, gender identity/sexual orientation, age and/or language preference.

³ (b) Third-party reporting is used to calculate the number of people reached through social investments. In some cases, third-party reports may include cumulative people reached for the reporting period, and/or data that are attributable to other partners as well as our Company's philanthropic investment.